Publications

Timothy Burns, MD, PHD

Bossart EA, Tasdemir N, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res Treat. 2019 Jun;175(2):327-337. doi: 10.1007/s10549-019-05161-8. PubMed PMID: 30798422; PMCID: PMC6625318.
Yochum ZA, Burns TF. TWIST1 regulation of circRNA: a novel mechanism to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Noncoding RNA Investig. 2018 Dec;2 doi: 10.21037/ncri.2018.12.01. PubMed PMID: 30734026; PMCID: PMC6363344.
Yoon JH, Nouraie M, Chen X, Zou RH, Sellares J, Veraldi KL, Chiarchiaro J, Lindell K, Wilson DO, Kaminski N, Burns T, Trejo Bittar H, Yousem S, Gibson K, Kass DJ. Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data. Respir Res. 2018 Oct 3;19(1):195. doi: 10.1186/s12931-018-0899-4. PubMed PMID: 30285867; PMCID: PMC6171146.
Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, Rudin CM, Tran PT, Burns TF. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. PubMed PMID: 30171258; PMCID: PMC6358506.
Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. PubMed PMID: 29880613; PMCID: PMC6119152.
Han J, Goldstein LA, Hou W, Chatterjee S, Burns TF, Rabinowich H. HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC. Autophagy. 2018;14(6):958-971. doi: 10.1080/15548627.2018.1434471. PubMed PMID: 29561705; PMCID: PMC6103412.
Volonte D, Vyas AR, Chen C, Dacic S, Stabile LP, Kurland BF, Abberbock SR, Burns TF, Herman JG, Di YP, Galbiati F. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. PubMed PMID: 29247004; PMCID: PMC5798308.
Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. Mol Cancer Ther. 2018 Apr;17(4):806-813. doi: 10.1158/1535-7163.MCT-17-0561. PubMed PMID: 29167314; PMCID: PMC5882543.
Ancevski Hunter K, Friedland DM, Villaruz LC, Burns TF. First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC. J Thorac Oncol. 2018 Jan;13(1):e3-e5. doi: 10.1016/j.jtho.2017.09.1963. PubMed PMID: 28989039.
Chatterjee S, Burns TF. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. Int J Mol Sci. 2017 Sep 15;18(9): doi: 10.3390/ijms18091978. PubMed PMID: 28914774; PMCID: PMC5618627.
Godse NR, Khan N, Yochum ZA, Gomez-Casal R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns TF, Duvvuri U. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res. 2017 Dec 1;23(23):7324-7332. doi: 10.1158/1078-0432.CCR-17-1561. PubMed PMID: 28899969; PMCID: PMC5898434.
Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh JA, Ewald AJ, Cho YJ, Rudin CM, Tran PT, Burns TF. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Mol Cancer Res. 2017 Dec;15(12):1764-1776. doi: 10.1158/1541-7786.MCR-17-0298. PubMed PMID: 28851812; PMCID: PMC5712248.
Chatterjee S, Huang EH, Christie I, Burns TF. Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC. Mol Cancer Ther. 2017 Aug;16(8):1658-1668. doi: 10.1158/1535-7163.MCT-17-0114. PubMed PMID: 28566436; PMCID: PMC5544554.
Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. PubMed PMID: 28472537; PMCID: PMC5517339.
Somasundaram A, Burns TF. The next generation of immunotherapy: keeping lung cancer in check. J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5. PubMed PMID: 28434399; PMCID: PMC5402056.
Somasundaram A, Burns TF. Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer (Auckl). 2017;81-11. doi: 10.2147/LCTT.S105678. PubMed PMID: 28293123; PMCID: PMC5342609.
Chatterjee S, Huang EH, Christie I, Kurland BF, Burns TF. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. Mol Cancer Ther. 2017 May;16(5):793-804. doi: 10.1158/1535-7163.MCT-16-0677. PubMed PMID: 28167505; PMCID: PMC5418121.
Yochum ZA, Socinski MA, Burns TF. Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance. J Thorac Dis. 2016 Nov;8(11):E1528-E1531. doi: 10.21037/jtd.2016.11.59. PubMed PMID: 28066651; PMCID: PMC5179406.
Chatterjee S, Bhattacharya S, Socinski MA, Burns TF. HSP90 inhibitors in lung cancer: promise still unfulfilled. Clin Adv Hematol Oncol. 2016 May;14(5):346-56. PubMed PMID: 27379696.
Davar D, Socinski MA, Dacic S, Burns TF. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp Hematol Oncol. 2015;434. doi: 10.1186/s40164-015-0029-7. PubMed PMID: 26673119; PMCID: PMC4678465.
Bhattacharya S, Socinski MA, Burns TF. KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Clin Transl Med. 2015 Dec;4(1):35. doi: 10.1186/s40169-015-0075-0. PubMed PMID: 26668062; PMCID: PMC4678136.
Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, Malek R, Taparra K, Cades J, Annadanam A, Yoon AR, Fertig E, Firulli BA, Mazzacurati L, Burns TF, Firulli AB, An SS, Tran PT. Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells. Neoplasia. 2015 Jan;17(1):16-31. doi: 10.1016/j.neo.2014.10.009. PubMed PMID: 25622896; PMCID: PMC4309734.
Somasundaram A, Socinski MA, Burns TF. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opin Pharmacother. 2014 Dec;15(18):2693-708. doi: 10.1517/14656566.2014.971013. PubMed PMID: 25381900.

<< Investigators Search

Top